X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6424) 6424
Publication (330) 330
Newsletter (65) 65
Book Review (25) 25
Book Chapter (9) 9
Conference Proceeding (3) 3
Magazine Article (3) 3
Dissertation (2) 2
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4198) 4198
vincristine - pharmacology (2493) 2493
oncology (2065) 2065
animals (2028) 2028
male (2001) 2001
female (1984) 1984
vincristine (1834) 1834
vincristine - administration & dosage (1488) 1488
antineoplastic combined chemotherapy protocols - therapeutic use (1365) 1365
index medicus (1246) 1246
pharmacology & pharmacy (1153) 1153
middle aged (1138) 1138
adult (1105) 1105
mice (1073) 1073
chemotherapy (1002) 1002
antineoplastic agents - pharmacology (943) 943
cancer (872) 872
doxorubicin - administration & dosage (836) 836
aged (811) 811
cyclophosphamide - administration & dosage (810) 810
doxorubicin - pharmacology (693) 693
drug resistance (662) 662
vincristine - therapeutic use (653) 653
prednisone - administration & dosage (613) 613
tumor cells, cultured (606) 606
p-glycoprotein (581) 581
dose-response relationship, drug (570) 570
cell line, tumor (561) 561
adolescent (550) 550
rats (531) 531
antineoplastic combined chemotherapy protocols - adverse effects (503) 503
child (485) 485
treatment outcome (468) 468
antineoplastic agents, phytogenic - pharmacology (466) 466
doxorubicin (466) 466
expression (438) 438
time factors (436) 436
apoptosis (435) 435
drug resistance, neoplasm (432) 432
antineoplastic combined chemotherapy protocols - administration & dosage (431) 431
multidrug resistance (430) 430
cell survival - drug effects (423) 423
vinblastine - pharmacology (399) 399
vincristine - adverse effects (395) 395
prognosis (391) 391
combined modality therapy (375) 375
biochemistry & molecular biology (366) 366
drug resistance, multiple (366) 366
cell line (345) 345
etoposide - administration & dosage (343) 343
apoptosis - drug effects (340) 340
cyclophosphamide (339) 339
hematology (329) 329
drug synergism (320) 320
child, preschool (319) 319
therapy (302) 302
cell division - drug effects (299) 299
verapamil - pharmacology (292) 292
cyclophosphamide - therapeutic use (291) 291
doxorubicin - therapeutic use (289) 289
tumor cells, cultured - drug effects (286) 286
vinblastine (286) 286
methotrexate - administration & dosage (285) 285
disease-free survival (284) 284
drug administration schedule (280) 280
leukemia (277) 277
multidrug-resistance (272) 272
antineoplastic agents - therapeutic use (256) 256
kinetics (256) 256
prednisone - therapeutic use (256) 256
rituximab (251) 251
survival analysis (251) 251
neoplasm staging (249) 249
lymphoma, non-hodgkin - drug therapy (248) 248
antineoplastic agents (246) 246
children (242) 242
cells (240) 240
care and treatment (236) 236
survival rate (234) 234
research (232) 232
cells, cultured (228) 228
bleomycin - administration & dosage (226) 226
medicine & public health (225) 225
colchicine - pharmacology (223) 223
pharmacology/toxicology (223) 223
analysis (222) 222
lung neoplasms - drug therapy (219) 219
drug screening assays, antitumor (218) 218
antineoplastic combined chemotherapy protocols - pharmacology (216) 216
in-vitro (216) 216
remission induction (213) 213
vincristine - metabolism (213) 213
atp-binding cassette, sub-family b, member 1 - metabolism (212) 212
infant (211) 211
cyclophosphamide - pharmacology (210) 210
aged, 80 and over (209) 209
survival (208) 208
drug-resistance (206) 206
cisplatin - pharmacology (204) 204
etoposide - pharmacology (204) 204
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6179) 6179
Chinese (103) 103
Japanese (60) 60
German (59) 59
French (29) 29
Russian (22) 22
Italian (20) 20
Polish (13) 13
Spanish (10) 10
Dutch (2) 2
Danish (1) 1
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Letters, ISSN 0304-3835, 2016, Volume 383, Issue 2, pp. 309 - 317
Abstract In previous studies we demonstrated that targeting the nuclear exporter protein exportin-1 (CRM1/XPO1) by a selective inhibitor of nuclear export... 
Hematology, Oncology and Palliative Medicine | NHL | XPO1 | Selective inhibitors of nuclear export | SINE | CRM1 | Exportin-1 | SURVIVAL | DRUG-RESISTANCE | MODEL | CANCER | STRATEGIES | ONCOLOGY | LINE | CHOP | PROTEINS | Vincristine - pharmacology | TOR Serine-Threonine Kinases - metabolism | Transcription Factor RelA - antagonists & inhibitors | Apoptosis - drug effects | Humans | Lymphoma, Non-Hodgkin - enzymology | Lymphoma, Non-Hodgkin - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Dexamethasone - pharmacology | Time Factors | Oxadiazoles - pharmacology | Acrylamides - pharmacology | Lymphoma, Non-Hodgkin - drug therapy | Cell Survival - drug effects | Hydrazines - pharmacology | Everolimus - pharmacology | Mice, SCID | Mice, Inbred ICR | Drug Synergism | Triazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Karyopherins - metabolism | Signal Transduction - drug effects | Transcription Factor RelA - metabolism | Tumor Burden - drug effects | Active Transport, Cell Nucleus - drug effects | Cyclophosphamide - pharmacology | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Cell Line, Tumor | Prednisone - pharmacology | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Karyopherins - antagonists & inhibitors | Doxorubicin - pharmacology | Receptors, Cytoplasmic and Nuclear - metabolism | International trade | Cyclophosphamide | Care and treatment | Dexamethasone | Analysis | Lymphomas | Prednisone | Exports | Steroids | Cancer | Drugs | TOR protein | Animal models | Laboratories | Toxicity | Xenotransplantation | Clinical trials | Cytotoxicity | Kinases | Experiments | Anticancer properties | Proteins | Cell growth | Antitumor agents | Cell cycle | Xenografts | Biocompatibility | Localization | Drug dosages | NF-κB protein | Chronic lymphatic leukemia | Hematology | Pharmacology | Chemical compounds | Patients | Lymphoma | Nuclear transport | Studies | Inhibitors | Response rates | In vivo methods and tests | Apoptosis
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, p. e111840
Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and... 
PROTEIN METHYLTRANSFERASES | SELECTIVE-INHIBITION | MOLECULAR SUBTYPES | APOPTOSIS | B-CELL LYMPHOMA | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | RESISTANCE | MECHANISMS | CANCER | SOMATIC MUTATIONS | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Neoplasm Transplantation | Vincristine - pharmacology | Humans | Receptors, Glucocorticoid - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Receptors, Glucocorticoid - agonists | Dexamethasone - pharmacology | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Drug Evaluation, Preclinical | Lymphoma, Non-Hodgkin - drug therapy | Enhancer of Zeste Homolog 2 Protein - metabolism | Random Allocation | Mice, SCID | Prednisolone - pharmacology | Animals | Cyclophosphamide - pharmacology | Lymphoma, Non-Hodgkin - metabolism | Cell Line, Tumor | Glucocorticoids - pharmacology | Prednisone - pharmacology | Doxorubicin - pharmacology | Pyridones - pharmacology | Care and treatment | Corticosteroids | Fluocinolone acetonide | Central nervous system depressants | Analysis | Histones | Models | Non-Hodgkin's lymphomas | Immunosuppressive agents | Steroids | Cancer | Signal transduction | Enzymes | Cell growth | Glucocorticoids | Research & development--R&D | Lymphomas | Mutation | Gene expression | Apoptosis
Journal Article
Cancer Cell, ISSN 1535-6108, 2007, Volume 12, Issue 2, pp. 171 - 185
Cancer cells exhibit many abnormal phenotypes that induce apoptotic signaling via the intrinsic, or mitochondrial, pathway. That cancer cells nonetheless... 
CELLCYCLE | MITOCHONDRIAL-MEMBRANE PERMEABILIZATION | B-CELL LYMPHOMA | ONCOLOGY | PROTOTYPE CANCER THERAPEUTICS | CHROMOSOMAL BREAKPOINT | FOLLICULAR LYMPHOMA | INDUCE APOPTOSIS | CYTOCHROME-C RELEASE | BCL-2 FAMILY-MEMBERS | BH3-ONLY PROTEINS | ANTIAPOPTOTIC BCL-2 | Vincristine - pharmacology | Immunoprecipitation | Proto-Oncogene Proteins c-bcl-2 - physiology | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Humans | Immunoblotting | Lymphoma, B-Cell - genetics | Bcl-2-Like Protein 11 | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Apoptosis Regulatory Proteins - genetics | Membrane Proteins - metabolism | BH3 Interacting Domain Death Agonist Protein - metabolism | Lymphoma, B-Cell - drug therapy | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Membrane Proteins - genetics | Tumor Cells, Cultured - drug effects | Etoposide - pharmacology | Proto-Oncogene Proteins - genetics | Sulfonamides - pharmacology | Piperazines - pharmacology | Blotting, Western | Apoptosis Regulatory Proteins - metabolism | Membrane Proteins - antagonists & inhibitors | Apoptosis Regulatory Proteins - antagonists & inhibitors | Lymphoma, B-Cell - pathology | Apoptosis Regulatory Proteins - physiology | Antineoplastic Agents, Phytogenic - pharmacology | Lymphoma, Large B-Cell, Diffuse - genetics | Doxorubicin - pharmacology
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2014, Volume 111, Issue 4, pp. 716 - 725
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 11/2012, Volume 9, Issue 11, pp. 3147 - 3159
23-O-(1,4'-Bipiperidine-1-carbonyl)betulinic acid (BBA), a synthetic derivative of 23-hydroxybetulinic acid (23-HBA), shows a reversal effect on multidrug... 
BBA | multidrug resistance | ABCB1 | ABCG2 | CANCER-CELLS | MEDICINE, RESEARCH & EXPERIMENTAL | HEPATOCELLULAR-CARCINOMA CELLS | MEDIATED MULTIDRUG-RESISTANCE | TRANSPORTERS | VINCRISTINE RESISTANCE | HUMAN P-GLYCOPROTEIN | GENE | PHARMACOLOGY & PHARMACY | ANTICANCER DRUGS | BINDING | CYTOTOXICITY | Paclitaxel - pharmacology | Triterpenes - pharmacology | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Drug Resistance, Multiple - drug effects | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Male | Breast Neoplasms - metabolism | Triterpenes - chemistry | Carcinoma, Hepatocellular - drug therapy | Piperidines - pharmacology | Triterpenes - chemical synthesis | Female | Antineoplastic Agents - pharmacology | Real-Time Polymerase Chain Reaction | Camptothecin - analogs & derivatives | RNA, Messenger - genetics | Cells, Cultured | Liver Neoplasms - drug therapy | Models, Molecular | Cisplatin - pharmacology | KB Cells - drug effects | Calcium Channel Blockers - pharmacology | Piperidines - chemical synthesis | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Verapamil - pharmacology | Blotting, Western | Animals | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Mice, Nude | Fluorescent Antibody Technique | Liver Neoplasms - metabolism | ATP Binding Cassette Transporter, Sub-Family B | Cell Proliferation - drug effects | Mice | Molecular Docking Simulation | Antineoplastic Agents, Phytogenic - pharmacology | In Vitro Techniques | Camptothecin - pharmacology | Doxorubicin - pharmacology | Carcinoma, Hepatocellular - metabolism | Drug Resistance, Neoplasm - drug effects
Journal Article
Journal Article
Oncology Reports, ISSN 1021-335X, 2/2014, Volume 31, Issue 2, pp. 955 - 968
Histone deacetylase inhibitors and bisphosphonates have a promising future in the treatment of cancer as targeted anticancer drugs, particularly when used... 
adjuvant therapy | Ewing sarcoma | sodium butyrate | chemotherapy | zoledronic acid | synergistic effect | Zoledronic acid | Sodium butyrate | Chemotherapy | Synergistic effect | Adjuvant therapy | CELLS | COMBINATION | FAMILY | BISPHOSPHONATES | ONCOLOGY | OSTEOSARCOMA | BONE | HISTONE DEACETYLASE INHIBITORS | TUMOR-GROWTH | Cell Survival - drug effects | Tumor Stem Cell Assay | Vincristine - pharmacology | Antibiotics, Antineoplastic - pharmacology | Humans | Etoposide - pharmacology | Imidazoles - pharmacology | Molecular Targeted Therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Bone Density Conservation Agents - pharmacology | Sarcoma, Ewing - drug therapy | Drug Synergism | Cell Line, Tumor | Histamine Antagonists - pharmacology | Histone Deacetylase Inhibitors - pharmacology | Butyric Acid - pharmacology | Cell Proliferation - drug effects | Antineoplastic Agents, Phytogenic - pharmacology | Diphosphonates - pharmacology | Doxorubicin - pharmacology | Pharmacology, Experimental | Enzyme inhibitors | Diphosphonates | Oncology, Experimental | Research | Drug therapy | Health aspects | Ewing's sarcoma | Drug synergism | Cancer | Medical research | Genes | Cytotoxicity | Cancer therapies | Proteins | Acids | Sodium | Medical prognosis | Cell cycle | Epigenetics | Drug dosages | Tumors | Apoptosis
Journal Article
Nature, ISSN 0028-0836, 09/2017, Volume 549, Issue 7670, pp. 96 - 100
Paediatric solid tumours arise from endodermal, ectodermal, or mesodermal lineages(1). Although the overall survival of children with solid tumours is 75%,... 
MULTIPLE-MYELOMA | HETEROGENEITY | BIOBANK | GENOMIC LANDSCAPE | MODELS | MULTIDISCIPLINARY SCIENCES | BORTEZOMIB | INHIBITOR | CANCER | DISCOVERY | PANOBINOSTAT LBH589 | Vincristine - pharmacology | Pyrazoles - therapeutic use | Epigenesis, Genetic | Heterografts - drug effects | Humans | Heterografts - metabolism | Bortezomib - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Neoplasms - genetics | Female | Indoles - pharmacology | Rhabdomyosarcoma - drug therapy | Clone Cells | Drug Therapy, Combination | Child | Heterografts - pathology | Hydroxamic Acids - pharmacology | Camptothecin - analogs & derivatives | High-Throughput Screening Assays - methods | Pyrazoles - pharmacology | Camptothecin - therapeutic use | Pyrimidines - pharmacology | Xenograft Model Antitumor Assays - methods | Neoplasms - drug therapy | Animals | Bortezomib - therapeutic use | Pyrimidines - therapeutic use | Nuclear Proteins - antagonists & inhibitors | Heterografts - transplantation | Vincristine - therapeutic use | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Mice | Rhabdomyosarcoma - genetics | Camptothecin - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Tumors in children | Care and treatment | Diagnosis | Xenotransplantation | Methods | Pediatrics | Rhabdomyosarcoma | Multiple myeloma | Genomes | Neuroblastoma | Gene expression | Vincristine | Patients | Children & youth | Irinotecan | Chemotherapy | Autopsy | Xenografts | Mutation | Children | Cancer | Tumors
Journal Article
Journal Article